Mary Holloway is a sought-after advisor, trainer, consultant and keynote speaker in the life science industry. Mary brings over 25 years of strategic experience on the commercial side of biopharmaceutical sales, training and marketing operations.Mary is well known and respected for the development and delivery of real-world consulting solutions and training strategies that maximize the value of commercial and field medical operations and improve field force effectiveness.
Mary co-founded DMH BioPharm Advisors, a boutique biopharmaceutical, medical device and life science consulting and training firm in 2008. DMH is a recognized leader in the creation and delivery of real-world training for marketing, sales, account teams and field-based medical colleagues. DMH has authored over 7 industry published articles and is an invited main podium speaker at industry events in the biopharmaceutical, medical affairs, biopharmaceutical training and compliance space.
Mary is known as an expert resource and dedicated life science industry advocate, she has helped countless organizations improve their field force, medical team, and account team’s field effectiveness. In addition, she has helped organizations create a positive compliance brand and aided in the development of ethical leaders.
Mary began her career with Pfizer Inc. as a field sales representative and, after four promotions in seven years, rose to the position of Area Sales Director. In every position, Mary was the recipient of her companies’ highest awards in sales and sales management. Mary’s stellar performance afforded her the opportunity to participate in various headquarters commercial advisory boards and task forces.
Throughout her career, Mary gained many valuable experiences that provide her with an ability to translate real world knowledge and experience to her clients. She has successfully trained and led teams of over 100 sales representatives and sales managers with budgets exceeding $1 billion. She has successfully launched 16 products and has broad therapeutic, disease state and marketplace knowledge in primary care, specialty and hospital markets. She has a first-hand understanding of field force processes and most importantly the mindset of biopharmaceutical field facing teams.
Mary has experience collaborating with headquarters commercial operations executives. She has worked with in-house and external legal counsel on government investigations. In addition, Mary has unique experience with the Department of Justice on off-label investigations regarding individuals and corporations. Through these experiences, Mary understands the risks that individuals and corporations operating in today’s regulatory environment face. She knows the red flags and where to look for them. Mary has developed an astute commercial and personal perspective that allows her to provide a wide variety of practical, actionable and valuable solutions to augment corporate compliance programs. Mary is a biopharmaceutical industry advocate who assists her clients in gaining commercial buy-in to their compliance initiatives and will help harmonize the inherent tensions between sales/marketing and legal/compliance teams.
In addition to her business acumen, Mary has exceptionally strong training and platform speaking skills. She is known as a dynamic communicator with an ability to teach, train, motivate, guide and inspire both large and small groups of individuals. She has developed curriculum for training programs that will truly get the attention of your executive leadership, field medical and sales force teams.
Mary holds a Bachelor’s Degree from Bowling Green State University and a certification in healthcare compliance from Seton Hall Law School. As an invited main podium speaker at industry conferences and events, Mary has presented on healthcare industry trends, healthcare compliance, effective and ethical promotion and medical affairs strategies. Mary recently spoke at 2017 Medical Affairs Professional Society’s Annual Meeting on “Understanding the FDA’s Draft Guidance on HCEI Communication with Payors, Formulary Committees and Similar Entities.”